Aktiesnakken — December 2009
-
de taler nu om at gå headtohead mod erbitux der omsætter for 1,7 mia dollar om året
-
de har hele tiden hævdet at zalutumuligmab er et bedre stof. De har et survival studie i slut fase 3 nu
-
ja det skal man nok
-
så køre vi aka
-
gå lige på skypew
-
sgu ikke mange aktier jeg kan købe til porten.....
-
-
igen voldsom køberinteresse i luk for genmab
-
ges luk i 22,30.... man tror jo næppe sine egne øjne....
-
stinker.... set HH's udvikling idag....? så bizart... og så frustrerende ikke at kunne shorte noget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind